UCSD vs. City of Hope Face-Off: Non–Small Cell Lung Cancer (NSCLC)
EP. 1: Introduction of the UCSD vs City of Hope Face-Off
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Edward Kim, MD, introduces a CancerNetwork® Face-Off program in which University of California San Diego and City of Hope will present clinical trial data and discuss treatment practices in non–small cell lung cancer (NSCLC).
EP. 2: Advanced ALK-Rearranged NSCLC
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Karen Yun, MD, opens the discussion by presenting data from the ALTA-1L and BRIGHTSTAR studies on advanced ALK-rearranged non–small cell lung cancer.
EP. 3: Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Erminia Massarelli, MD, PhD, MS, presents 5-year progression-free survival and safety data from the CROWN study comparing lorlatinib with crizotinib in treatment-naïve patients with advanced ALK+ NSCLC.
EP. 4: CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Amanda Herrmann, MD, discusses findings from the 5-year update from CheckMate-9LA investigating nivolumab, ipilimumab, and chemotherapy in patients with metastatic NSCLC.
EP. 5: Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Jyoti Malhotra, MD, MPH, reviews data from the phase III POSEIDON study evaluating durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for patients with metastatic NSCLC.
EP. 6: A Case of Metastatic ROS1 Fusion-Positive NSCLC
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Initiating a conversation on patient cases, Karen Yun, MD, presents the profile of a patient with metastatic ROS1 fusion-positive non–small cell lung cancer.
EP. 7: Patient Profile: EGFRm Post-Osimertinib
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Ramya Muddasani, DO, MS, presents the case of a patient with EGFR-mutated NSCLC following osimertinib treatment and shares insights gleaned from the INSIGHT 2 trial.
EP. 8: Patient Case: PD-L1 Negative NSCLC
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Sandip P. Patel, MD, reviews the case of a patient with PD-L1–negative NSCLC and discusses treatment practices.
EP. 9: KRAS Patient Case
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Ramya Muddasani, DO, MS, leads a discussion on the treatment of a patient with metastatic NSCLC with a KRAS G12C mutation, highlighting the utilization of sotorasib and the CodeBreaK 100 trial.
EP. 10: Neoadjuvant Chemoimmunotherapy for Resectable NSCLC
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Karen M. Yun, MD, discusses the role for neoadjuvant chemoimmunotherapy in patients with resectable non–small cell lung cancer.
EP. 11: Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.
EP. 12: Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Focusing on data from the FLAURA2 study, Erminia Massarelli, MD, PhD, MS, outlines the role of EGFR TKI plus chemotherapy for patients with EGFR-mutated NSCLC.
EP. 13: Treatment Options for Patients with EGFRm: EGFR TKI
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Continuing discussion on the treatment of patients with EGFR-mutated NSCLC, Sandip P. Patel, MD, discusses the role of EGFR TKIs without chemotherapy.
EP. 14: Face-Off: Award Ceremony
ByEdward Kim, MD,Misako Nagasaka, MD,Terence T. Sio, MD, MS,Sandip Patel, MD,Karen M. Yun, MD,Amanda Herrmann, MD,Jyoti Malhotra, MD, MPH,Erminia Massarelli, MD, PhD, MS,Ramya Muddasani, DO, MS Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
